Remove Food and Drug Administration Remove Leads Remove Medical Remove Patients
article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

In many European countries physicians can now prescribe medical cannabis for an array of chronic health conditions, including chronic pain, mental health disorders and neurological conditions. 1 In many countries, medical cannabis is only utilised as a therapy when licensed medications have proven ineffective.

Medical 82
article thumbnail

A scientific approach to irrational consumer choices

World of DTC Marketing

GOOD MORNING: The FDA is taking a scientific approach to evaluating direct-to-consumer (DTC) drug advertising, focusing on measuring consumer perceptions of the information presented in ads. Presenting quantitative information increased participants’ gist and verbatim recall of drug efficacy. ” Uh…no.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How the US’s pending PIE Act will improve patient access to medication

pharmaphorum

7008), which allows manufacturers to share vital information with healthcare payers and plans while treatments are pending Food and Drug Administration (FDA) approval, was passed by the House of Representatives and is awaiting approval in the Senate. Affecting patient care. The AMCP backed bill (H.R.

article thumbnail

Parkinson’s infusion treatment demonstrates advantage over oral delivery

European Pharmaceutical Review

A Phase III trial has shown that compared oral drug delivery, administering levodopa through an infusion pump led to nearly two hours of day (1.72) of additional time in which the medicine reduced symptoms in Parkinson’s patients. There were 381 Parkinson’s patients enrolled in the trial. and Joan A.

article thumbnail

FDA grants Orphan Drug status to Ocelot’s hepatorenal syndrome therapy

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Ocelot Bio’s OCE-205 to treat hepatorenal syndrome. A lead candidate of the company, OCE-205 is a peptide therapeutic. It will analyse the safety and efficacy of OCE-205 in adult HRS-AKI patients having cirrhosis with ascites.

article thumbnail

Novel haemophilia B gene therapy approved

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved the adeno-associated virus (AAV)-based gene therapy BEQVEZ (fidanacogene elaparvovec-dzkt) for certain adults with haemophilia B. This authorisation of BEQVEZ is based on results from the pivotal Phase III BENEGENE-2 study.

article thumbnail

Recor Medical and Otsuka Medical Devices Announce Positive Vote from the FDA Advisory Committee Meeting on the Paradise™ Ultrasound Renal Denervation System

Legacy MEDSearch

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Otsuka Medical Devices”) announce the U.S. The overall vote from the committee was favorable that there was sufficient data to support the use of the device in patients with uncontrolled hypertension. About Recor Medical, Inc.

Medical 52